Search

Displaying results 411 - 420 of 1917 in total
  1. Drug

    Dexketoprofen

    go.drugbank.com/drugs/DB09214
    ApprovedInvestigationalWithdrawn

    It is available in the various countries in Europe, Asia and Latin America. It has analgesic, antipyretic and anti-inflammatory properties [L1298].

  2. Drug

    Pilocarpine

    go.drugbank.com/drugs/DB01085
    ApprovedInvestigational

    A naturally occurring alkaloid derived from the Pilocarpus plants, pilocarpine is a muscarinic acetylcholine agonist. Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine ...

  3. Drug

    Branaplam

    go.drugbank.com/drugs/DB14918
    Investigational

    Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).

  4. Drug

    Parsaclisib

    go.drugbank.com/drugs/DB14867
    Investigational

    Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).

  5. Drug

    Guvacine

    go.drugbank.com/drugs/DB08848
    Experimental

    Guvacine is a pyridine alkaloid found in the Areca nut (also known as the Betel nut). It is an experimental drug with no approved indication. … Currently it has been determined that guvacine is a specific GABA reuptake inhibitor with no significant affinity at GABA receptors.

  6. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.

  7. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and

  8. Drug

    Duloxetine

    go.drugbank.com/drugs/DB00476
    ApprovedInvestigational

    Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymb...

    Synonyms: (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amineProducts: Nb-duloxetine, DU-TWO ® 30 MG
  9. Drug

    Flubendazole

    go.drugbank.com/drugs/DB08974
    ApprovedInvestigationalWithdrawn

    It is available OTC in Europe.

  10. Drug

    Abiraterone decanoate

    go.drugbank.com/drugs/DB18905
    Investigational

    Abiraterone decanoate is under investigation in clinical trial NCT04729114 (Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer).